849943-17-5

Basic information

• Product Name: 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)-
• CAS NO: 849943-17-5
• Molecular Formula: C17H21N5OS2
• Molecular Weight: 375.519
• Mol File: 849943-17-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)-(849943-17-5)
• EPA Substance Registry System: 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)-(849943-17-5)

Safety Data

• Hazardous Substances Data: 849943-17-5(Hazardous Substances Data)

Upstream product

• 259103-38-3 7-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-amine 
• 80696-30-6 (2R)-2-aminopentan-1-ol 
• 37660-23-4 4-amino-2-(benzylthio)-6-hydroxypyrimidine 
• 259103-40-7 {[4-amino-2-(benzylsulfanyl)-6-hydroxypyrimidin-5-yl]sulfanyl}formonitrile 
• 259100-47-5 2-amino-5-(benzylsulfanyl)[1,3]thiazolo[4,5-d]pyrimidin-7-ol 
• 100-39-0 benzyl bromide 

Downstream Products

• 911715-95-2 3-{(1S)-1-[(2-chloro-7-{[(2R)-1-hydroxypentan-2-yl]amino}[1,3]thiazolo[4,5-d]pyrimidin-5-yl)sulfanyl]ethyl}benzonitrile 
• 911715-96-3 3-{(1S)-1-[(7-{[(2R)-1-hydroxypentan-2-yl]amino}-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-5-yl)sulfanyl]ethyl}benzonitrile 
• 849943-18-6 (2R)-2-{[5-(benzylthio)-2-chloro[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino}pentan-1-ol 

Relevant articles and documents

Substituted 7-amino-5-thio-thiazolo[4,5- d ]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1)

We have developed two parallel series, A and B, of CX3CR1 antagonists for the treatment of multiple sclerosis. By modifying the substituents on the 7-amino-5-thio-thiazolo[4,5-d]pyrimidine core structure, we were able to achieve compounds with high selectivity for CX3CR1 over the closely related CXCR2 receptor. The structure-activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with α-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18a and 24h. We show the preparation of the first potent and selective orally available CX3CR1 antagonists.

NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DEREVATIVES AND THEIR USE IN THERAPY

There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3#191CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.

NOVEL 5-SUBSTITUTED 7-AMINO-[1,3]THIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES

There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically accept